Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
skip to main content

Promising stem cell therapy for atopic dermatitis

Published: June 27, 2024

Seo et al. conducted a groundbreaking Phase I/II clinical trial exploring the use of human bone marrow-derived clonal mesenchymal stem cells (hcMSCs) for the treatment of moderate-to-severe atopic dermatitis (AD), a chronic inflammatory skin condition. With the rising prevalence of AD, particularly in adults, the search for safe and effective long-term treatments is critical.

The study, as published in The Journal of Allergy and Clinical Immunology (JACI) by Seo et al., began with a Phase I trial focusing on the safety of hcMSC therapy. This phase involved 20 adult subjects with moderate-to-severe atopic dermatitis, each receiving three intravenous infusions of hcMSCs. The results showed that the treatment was well-tolerated, with no serious adverse effects, establishing a safe dosage for further research.

Phase II extended the investigation to 72 subjects in a double-blind, placebo-controlled setting. The findings revealed that subjects receiving hcMSCs experienced significantly greater improvement in their AD symptoms compared to those receiving a placebo. Notably, 57% of the hcMSC-treated subjects achieved a 50% reduction in the Eczema Area and Severity Index (EASI-50) at 12 weeks, compared to just 32% in the placebo group. The safety profile remained favorable, with most adverse events being acceptable.

In conclusion, this study presents hcMSC therapy as a promising treatment for moderate-to-severe AD, with a good safety profile and substantial efficacy. These findings support further research into the long-term benefits and underlying mechanisms of hcMSCs in managing AD.

The Journal of Allergy and Clinical Immunology (JACI) is an official scientific journal of the AAAAI, and is the most-cited journal in the field of allergy and clinical immunology.

Full Article